Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Inventory (2018 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Inventory for 8 consecutive years, with $37.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 90.19% year-over-year to $37.2 million, compared with a TTM value of $37.2 million through Dec 2025, up 90.19%, and an annual FY2025 reading of $37.2 million, up 90.19% over the prior year.
  • Inventory was $37.2 million for Q4 2025 at Catalyst Pharmaceuticals, up from $28.0 million in the prior quarter.
  • Across five years, Inventory topped out at $37.2 million in Q4 2025 and bottomed at $4.4 million in Q1 2021.
  • Average Inventory over 5 years is $14.1 million, with a median of $10.5 million recorded in 2023.
  • The sharpest move saw Inventory soared 288.25% in 2021, then fell 13.53% in 2022.
  • Year by year, Inventory stood at $7.9 million in 2021, then dropped by 13.53% to $6.8 million in 2022, then soared by 129.89% to $15.6 million in 2023, then grew by 24.91% to $19.5 million in 2024, then surged by 90.19% to $37.2 million in 2025.
  • Business Quant data shows Inventory for CPRX at $37.2 million in Q4 2025, $28.0 million in Q3 2025, and $18.6 million in Q2 2025.